Skip to main content

Table 2 Baseline Characteristics by Subset

From: A randomized, double-blind, placebo-controlled, multicenter study assessing the efficacy of magnesium oxide monohydrate in the treatment of nocturnal leg cramps

  Subset 1
(N = 44)
Subset 2
(N = 129)
P Value
Demographics
Gender Female n (%) 26 (59.1) 103 (79.8) 0.009
Age (years) mean (±SD) 50.0 (±6.1) 59.7 (±10.5) < 0.001
Weight (kg) mean (±SD) 75.6 (±16.1) 74.7 (±12.4) 0.638
Height (cm) mean (±SD) 171.4 (±12.5) 166.1 (±7.7) 0.001
BMI (kg/m2) mean (±SD) 25.5 (±3.4) 27.1 (±4.4) 0.108
Physiological parameters
Systolic blood pressure (mmHg) mean (±SD) 134.2 (±11.4) 127.7 (±10.2) < 0.001
Diastolic blood pressure (mmHg) mean (±SD) 83.4 (±5.2) 78.2 (±6.5) < 0.001
Heart rate (beats/min) mean (±SD) 70.6 (±5.0) 71.8 (±6.7) 0.429
Baseline efficacy parameters
NLC frequency (num/week) mean (±SD) 3.9 (±0.8) 6.6 (±7.9) 0.003
NLC duration (sec/week) mean (±SD) 48.7 (±12.9) 326.1 (±244.5) < 0.001
NLC pain (mean VAS/week) mean (±SD) 6.7 (±0.9) 6.6 (±1.6) 0.686
Sleep quality (mean cumulative score/week) mean (±SD) 13.0 (±2.9) 12.7 (±3.7) 0.627
  1. BMI body mass index, NLC nocturnal leg cramps, SD standard deviation, VAS visual analogue scale